Articles written by Vandana Singh - Benzinga

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

|CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older populations.

UK Becomes First Country To Authorize Blenrep In Two Combo Regimens

|GSK's Blenrep approved in the U.K. for multiple myeloma after strong phase 3 data showing improved survival in DREAMM-7 and DREAMM-8 trials.

Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential

|Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by 2030.

FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion

|FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

|uniQure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan Drug statuses.

Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars

|Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable safety profile.

UnitedHealth Slashes 2025 Outlook On Medicare Funding Reductions, Stock Crashes

|UnitedHealth missed Q1 earnings estimates, reported a 6.8% revenue rise, and cut its 2025 EPS guidance due to rising medical costs and Medicare shifts.

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch

|Mounjaro's launch in India sparks a surge in patient demand as Eli Lilly gains a market edge ahead of Novo Nordisk and upcoming generic competition.

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

|Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction

|Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.

Citigroup Price Target Trimmed As Analysts Fear Increased Macro Environment-Associated Uncertainty

|Citigroup beat Q1 revenue and earnings estimates, but analysts lowered EPS forecasts and price targets citing macro risks and credit concerns.

Bank Of America Analysts Cut Price Target Amid Macro Uncertainty, But Maintain Positive Outlook

|Bank of America beat Q1 expectations with $7.4 billion net income and $0.90 EPS as analysts trimmed future estimates but kept bullish outlooks.

Trump Administration Opens Probe Into Foreign Drug Imports, Eyes Tariffs Under National Security Law

|The U.S. Commerce Department has launched a Section 232 investigation into the national security impact of pharmaceutical and drug ingredient imports, citing supply chain risks.

Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion

|Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer's treatment.

Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients

|Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.

Abbott Labs Clocks Q1 Profit Beat, CEO Says Diversification And Execution Enable Navigation During Uncertainty

|Abbott reaffirmed its 2025 EPS guidance supported by strong Diabetes and Nutrition growth.

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

|MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in early 2026.

Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts

|FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility.

Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?

|Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

|Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential.